Cadisegliatin Trial
Phase 3
150
about 2.4 years
18+
50 sites in AR, AZ, CA +17
What this study is about
This trial is testing whether cadisegliatin, taken as a treatment alongside insulin, can help people with Type 1 Diabetes. Participants will take either cadisegliatin or a placebo for up to 869 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cadisegliatin 800 mg BID
- 2.Take Cadisegliatin 800 mg QD
- 3.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: To assess the change in HbA1c, To assess the effects of treatment on body weight, To assess the incidence of adverse events of special interest, To assess the incidence of treatment emergent adverse events, To assess the incidence of treatment emergent adverse events leading to discontinuation
Endocrinology